As patients with chronic myeloid leukemia (CML) fail on treatment and move to later lines of therapy, the impact on their health-related quality of life and the economic burden significantly increase.

Phase I/II study of the combination of inotuzumab ozogamicin (CMC-544) with low-intensity chemotherapy in patients (pts) with acute lymphoblastic leukemia (ALL). This is an ASCO Meeting Abstract from ...

CD96 antibody TH-111 for detection of AML leukemic stem cells, and purging of autografts for stem cell transplantation.